Bonnenfant04	S. Bonnenfant, C.M. Thomas, C. Vita, F. Subra, E. Deprez, F. Zouhiri, D. Desmaele, J. D'Angelo, J.F. Mouscadet, H. Leh	Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents	J Virol	78(11)	5728-36	2004	15140970	183	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15140970&dopt=Citation>15140970</a>	11Colson05	P. Colson, M. Henry, N. Tivoli, H. Gallais, J.A. Gastaut, J. Moreau, C. Tamalet	Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France	J Med Virol	75(3)	381-90	2005	15648062	185	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15648062&dopt=Citation>15648062</a>	3Damond05	F. Damond, F. Brun-Vezinet, S. Matheron, G. Peytavin, P. Campa, S. Pueyo, F. Mammano, S. Lastere, I. Farfara, F. Simon, G. Chene, D. Descamps	Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors	J Clin Microbiol	43(1)	484-7	2005	15635022	186	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15635022&dopt=Citation>15635022</a>	1DeMeyer05	S. De Meyer, H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, M.P. de Bethune	TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates	Antimicrob Agents Chemother	49(6)	2314-21	2005	15917527	187	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15917527&dopt=Citation>15917527</a>	6Doyon05	L. Doyon, S. Tremblay, L. Bourgon, E. Wardrop, M.G. Cordingley	Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir	Antiviral Res	68(1)	27-35	2005	16122817	188	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16122817&dopt=Citation>16122817</a>	1Johnston04	E. Johnston, M.A. Winters, S.Y. Rhee, T.C. Merigan, C.A. Schiffer, R.W. Shafer	Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance	Antimicrob Agents Chemother	48(12)	4864-8	2004	15561868	189	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15561868&dopt=Citation>15561868</a>	12Lohrengel05	S. Lohrengel, F. Hermann, I. Hagmann, H. Oberwinkler, L. Scrivano, C. Hoffmann, D. von Laer, M.T. Dittmar	Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides	J Virol	79(16)	10237-46	2005	16051817	190	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16051817&dopt=Citation>16051817</a>	16Matsuoka-Aizawa03	S. Matsuoka-Aizawa, H. Sato, A. Hachiya, K. Tsuchiya, Y. Takebe, H. Gatanaga, S. Kimura, S. Oka	Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication	J Virol	77(1)	318-27	2003	12477837	191	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12477837&dopt=Citation>12477837</a>	1Menzo04	Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M	Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment	New Microbiol	27 (2 Suppl 1)	51-61	2004	15646065	192	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15646065&dopt=Citation>15646065</a>	Ray05	A.S. Ray, B.I. Hernandez-Santiago, J.S. Mathew, E. Murakami, C. Bozeman, M.Y. Xie, G.E. Dutschman, E. Gullen, Z. Yang, S. Hurwitz, Y.C. Cheng, C.K. Chu, H. McClure, R.F. Schinazi, K.S. Anderson	Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine	Antimicrob Agents Chemother	49(5)	1994-2001	2005	15855524	193	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15855524&dopt=Citation>15855524</a>	5Svicher05	V. Svicher, F. Ceccherini-Silberstein, F. Erba, M. Santoro, C. Gori, M.C. Bellocchi, S. Giannella, M.P. Trotta, A. Monforte, A. Antinori, C.F. Perno	Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors	Antimicrob Agents Chemother	49(5)	2015-25	2005	15855527	194	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15855527&dopt=Citation>15855527</a>	5Wirden05	Wirden M, Marcelin AG, Simon A, Kirstetter M, Tubiana R, Valantin MA, Paris L, Bonmarchand M, Conan F, Kalkias L, Katlama C, Calvez V	Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients	J Med Virol	76(3)	297-301	2005	15902696	195	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15902696&dopt=Citation>15902696</a>	3Witvrouw05	M. Witvrouw, V. Fikkert, A. Hantson, C. Pannecouque, B.R. O'keefe, J. McMahon, L. Stamatatos, E. de Clercq, A. Bolmstedt	Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A	J Virol	79(12)	7777-84	2005	15919930	196	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15919930&dopt=Citation>15919930</a>	12Auwerx04	J. Auwerx, M. Stevens, A.R. Van Rompay, L.E. Bird, J. Ren, E. De Clercq, B. Oberg, D.K. Stammers, A. Karlsson, J. Balzarini	The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT	J Virol	78(14)	7427-37	2004	15220416	197	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15220416&dopt=Citation>15220416</a>	14Harrigan05	P.R. Harrigan, T. Mo, B. Wynhoven, J. Hirsch, Z. Brumme, P. McKenna, T. Pattery, J. Vingerhoets, L.T. Bacheler	Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors	AIDS	19(6)	549-54	2005	15802972	198	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15802972&dopt=Citation>15802972</a>	6Nitanda05	T. Nitanda, X. Wang, H. Kumamoto, K. Haraguchi, H. Tanaka, Y.C. Cheng, M. Baba	Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro	Antimicrob Agents Chemother	49(8)	3355-60	2005	16048947	199	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16048947&dopt=Citation>16048947</a>	8Paolucci04	S. Paolucci, F. Baldanti, G. Maga, R. Cancio, M. Zazzi, M. Zavattoni, A. Chiesa, S. Spadari, G. Gerna	Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication	Antimicrob Agents Chemother	48(12)	4611-7	2004	15561833	200	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15561833&dopt=Citation>15561833</a>	12Resch05	W. Resch, N. Parkin, T. Watkins, J. Harris, R. Swanstrom	Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir	J Virol	79(16)	10638-49	2005	16051856	201	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16051856&dopt=Citation>16051856</a>	16Mo05	Mo H, King MS, King K, Molla A, Brun S, Kempf DJ	Selection of Resistance in Protease Inhibitor- Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Mailing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates	J  Virol	79(6)	3329-3338	2005	15731227	202	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15731227&dopt=Citation>15731227</a>	Ochoa de Echaguen05	de Echaguen AO, Arnedo M, Xercavins M, Martinez E, Roson B, Ribera E, Domingo P, Gonzalez A, Riera M, Llibre JM, Gatell JM, Dalmau D, for the Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team	Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz, or abacavir	AIDS	19(13)	1385-1391	2005	16103769	203	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16103769&dopt=Citation>16103769</a>	Hachiya04	Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, Mitsuya H, Kimura S, Oka S	Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naive patients	Virology	327(2)	215-24	2004	15351209	204	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15351209&dopt=Citation>15351209</a>	Ariyoshi03	Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W	Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection	J Acquir Immune Defic Syndr	33(3)	336-42	2003	12843744	1	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12843744&dopt=Citation>12843744</a>	Bacheler00	Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K.	Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.	Antimicrobial Agents and Chemotherapy	44	2475-2484	2000	10952598	2	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10952598&dopt=Citation>10952598</a>	Balzarini93	J. Balzarini, A. Karlsson, E. De Clercq	Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.	Mol Pharmacol	44	694-701	1993	7694068	3	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7694068&dopt=Citation>7694068</a>	Balzarini93a	J. Balzarini, S. Velazquez, A. San-Felix, A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, E. De Clercq	Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5’’-(4’’-amino-1’’,2’’- oxathiole-2’’,2’’-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1- specific non-nucleoside analogues.	Mol Pharmacol	43	109-14	1993	7678689	4	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7678689&dopt=Citation>7678689</a>	Balzarini93b	J. Balzarini, A. Karlsson, E. De Clercq, J. Balzarini, A. Karlsson, A. M. Vandamme, M. J. Perez-Perez, H. Zhang, L. Vrang, B. Oberg, K. Backbro, T. Unge, A. San-Felix, et al	Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''- dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.	Proc Natl Acad Sci U S A	90	6952-6	1993	7688467	5	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7688467&dopt=Citation>7688467</a>	Balzarini93c	J. Balzarini, A. Karlsson, M. J. Perez-Perez, L. Vrang, J. Walbers, H. Zhang, B. Oberg, A. M. Vandamme, M. J. Camarasa, E. De Clercq	HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.	Virology	192	246-53	1993	7685964	6	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7685964&dopt=Citation>7685964</a>	Balzarini93d	J. Balzarini, A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, W. G. Tarpley, E. De Clercq	Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.	J Virol	67	5353-9	1993	7688822	7	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7688822&dopt=Citation>7688822</a>	Balzarini94	J. Balzarini, A. Karlsson, V. V. Sardana, E. A. Emini, M. J. Camarasa, E. De Clercq	Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-- >C181I)RT HIV-1 mutants.	Proc Natl Acad Sci U S A	91	6599-603	1994	7517553	8	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7517553&dopt=Citation>7517553</a>	Balzarini95	J. Balzarini, M. J. Perez-Perez, S. Velazquez, A. San-Felix, M. J. Camarasa, E. De Clercq, A. Karlsson	Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).	Proc Natl Acad Sci U S A	92	5470-4	1995	7539917	9	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7539917&dopt=Citation>7539917</a>	Balzarini96a	J. Balzarini, H. Pelemans, S. Aquaro, C. F. Perno, M. Witvrouw, D.Schols, E. De Clercq, A. Karlsson	Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.	Mol Pharmacol	50	394-401	1996	8700148	10	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8700148&dopt=Citation>8700148</a>	Balzarini96b	J. Balzarini, W. G. Brouwer, D. C. Dao, E. M. Osika, E. De Clercq	Identification of novel thiocarboxanilide derivatives that suppress a variety ofdrug-resistant mutant human immunodeficiency virus type 1 strains at a potencysimilar to that for wild-type virus.	Antimicrob Agents Chemother	40	1454-66	1996	8726019	11	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8726019&dopt=Citation>8726019</a>	Balzarini96c	Balzarini J, Pelemans H, Perez-Perez MJ, San-Felix A, Camarasa MJ, De Clercq E, Karlsson A	Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.	Mol Pharmacol 	49(5)	882-90	1996	8622638	12	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8622638&dopt=Citation>8622638</a>	Bazmi00	Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW	In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine	Antimicrob Agents Chemother	44(7)	1783-8	2000	10858331	13	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10858331&dopt=Citation>10858331</a>	Borkow03	Borkow G, Lara HH, Lapidot A	Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate	Biochem Biophys Res Commun	312(4)	1047-52	2003	14651977	14	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14651977&dopt=Citation>14651977</a>	Borman96	Borman AM, Paulous S, Clavel F	Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug	J Gen Virol	77 ( Pt 3)	419-26	1996	8601776 	15	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8601776 &dopt=Citation>8601776 </a>	BorrotoEsoda97	Borroto-K. Esoda, D.S. Noel, C.P. Moxham, Furman P.A.	Preliminary genotypic analysis of HIV-1 in plasma from volunteers receiving repeated multiple doses of MKC-442	Sixth International Workshop on HIV Drug Resistance St. Petersburg, FL, USA			1997		16		Brenner03	Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA	A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors	AIDS	17(1)	F1-5	2003	12478089	17	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12478089&dopt=Citation>12478089</a>	Brown00	Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar ES, D'Aquila RT, Keiser PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD, Little SJ.	Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1)from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.	Journal of Virology	74	10269-10273	2000	11044070	18	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11044070&dopt=Citation>11044070</a>	Buckheit95a	R. W. Buckheit, T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, et al	Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.	Antimicrob Agents Chemother	39	2718-27	1995	8593008	19	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8593008&dopt=Citation>8593008</a>	Buckheit95b	R. W. Buckheit, V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, T. L. Stup, C. A. Pyle, E. L. White, J. B. McMahon, M. J. Currens, M. R. Boyd, et al	Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.	Antiviral Res	26	117-32	1995	7541618	20	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7541618&dopt=Citation>7541618</a>	Buckheit95c	Buckheit RW Jr, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP	Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase	Virology	210	186-193	1995	7540784	21	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7540784&dopt=Citation>7540784</a>	Buckheit97	Buckheit RW Jr, Snow MJ, Fliakas-Boltz V, Kinjerski TL, Russell JD, Pallansch LA, Brouwer WG, Yang SS	Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.	Antimicrob Agents Chemother	41	831-837	1997	9087499	22	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9087499&dopt=Citation>9087499</a>	Bulgheroni04	Bulgheroni E, Croce F, Citterio P, Vigano O, Visona R, Sala E, Galli M, Rusconi S	Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility	J Clin Virol	29(1)	27-32	2004	14675866 	23	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14675866 &dopt=Citation>14675866 </a>	Byrnes93	V. W. Byrnes, V. V. Sardana, W. A. Schleif, J. H. Condra, J. A. Waterbury, J. A. Wolfgang, W. J. Long, C. L. Schneider, A. J. Schlabach, B. S. Wolanskii	Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.	Antimicrob Agents Chemother	37	1576-9	1993	7692811	24	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7692811&dopt=Citation>7692811</a>	Caride00	Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sa CA, Eyer-Silva WA, Sion FS, Passioni LF,Menezes JA, Calazans AR, Tanuri A.	Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) ofhuman immunodeficiency virus type I found in Brazilian patients failing HAART.	Virology	275	107-115	2000	11017792	25	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11017792&dopt=Citation>11017792</a>	Carrillo98	Carrillo A, Stewart KD, Norbeck DW, Kohlbrenner WE, Leonard JM, Kempf DJ, Molla A.	In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor	J Virol	72	7532-7541	1998	9696850	26	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9696850&dopt=Citation>9696850</a>	Cherrington96	J. M. Cherrington, A. S. Mulato, M. D. Fuller, M. S. Chen	Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2- (phosphonomethoxy)ethyl]adenine in vitro.	Antimicrob Agents Chemother	40	2212-6	1996	8878611	27	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8878611&dopt=Citation>8878611</a>	Condra95	J. H. Condra, W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, et al	In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors	Nature	374	569-71	1995	7700387	28	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7700387&dopt=Citation>7700387</a>	Condra96	Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA	Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor	J Virol	70(12)	8270-6	1996	8970946	29	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8970946&dopt=Citation>8970946</a>	Croteau97	G. Croteau, L. Doyon, D. Thibeault, G. McKercher, L. Pilote, D. Lamarre	Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.	J Virol	71	1089-96	1997	8995629	30	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8995629&dopt=Citation>8995629</a>	Cushman98	Cushman M, Casimiro-Barcia A, Hejchman E, Ruell JA, Huang M, Schaeffer CA, Williamson K, Rice WG, Buckheit Jr. RW.	New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.	J Med Chem	41	2076-2089	1998	9622549	31	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9622549&dopt=Citation>9622549</a>	DeAntoni97	A. De Antoni, A. Foli, J. Lisziewicz, F. Lori	Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy	J Infect Dis	176	899-903	1997	9333147	32	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9333147&dopt=Citation>9333147</a>	Demeter98	L. M. Demeter, P. M. Meehan, G. Morse, M. A. Fischl, M. Para, W. Powderly, J. Leedom, J. Holden-Wiltse, C. Greisberger, K. Wood, J. Timpone, L. K. Wathen, T. Nevin, L. Resnick, D. H. Batts, R. C. Reichman	Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1- infected patients	J Acquir Immune Defic Syndr Hum Retrovirol	19	135-44	1998	9768622	33	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9768622&dopt=Citation>9768622</a>	DeVreese96	K. De Vreese, D. Reymen, P. Griffin, A. Steinkasserer, G. Werner, G. J. Bridger, J. Este, W. James, G. W. Henson, J. Desmyter, J. Anne, I. De Clercq	The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.	Antiviral Res	29	209-19	1996	8739600	34	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8739600&dopt=Citation>8739600</a>	DeVreese96a	de Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anne J, de Clercq E, Datema R, Werner G	The molecular target of bicyclams, potent inhibitors of human immunodeficiencyvirus replication	J Virol	70(2)	689-96	1996	8551604	35	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8551604&dopt=Citation>8551604</a>	Doyon96	L. Doyon, G. Croteau, D. Thibeault, F. Poulin, L. Pilote, D. Lamarre	Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.	J Virol	70	3763-9	1996	8648711	36	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8648711&dopt=Citation>8648711</a>	Dueweke93	T. J. Dueweke, T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Chen, M. Stevenson, W. G. Tarpley	A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.	Proc Natl Acad Sci U S A	90	4713-7	1993	7685109	37	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7685109&dopt=Citation>7685109</a>	Dulioust97	A. Dulioust, S. Paulous, L. Guillemot, F. Boue, P. Galanaud, Clavel F	Selection of saquinavir-resistant mutants by indinavir following a switch from saquinavir	Sixth International Workshop on HIV Drug Resistance St. Petersburg, FL, USA			1997		38		Dulioust99	Dulioust A, Paulous S, Guillemot L, Delavalle AM, Boue F, Clavel F	Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors	J Virol	73(1)	850-4	1999	9847401	39	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9847401&dopt=Citation>9847401</a>	Eastman98	Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, Urdea M, Leonard JM, Norbeck DW, Mo H, Markowitz M	Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy	J Virol	72(6)	5154-64	1998	9573287	40	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9573287&dopt=Citation>9573287</a>	Eberle95	J. Eberle, B. Bechowsky, D. Rose, U. Hauser, K. von der Helm, L. Gurtler, H. Nitschko	Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.	AIDS Res Hum Retroviruses	11	671-6	1995	7576926	41	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7576926&dopt=Citation>7576926</a>	el-Farrash94	M. A. el-Farrash, M. J. Kuroda, T. Kitazaki, T. Masuda, K. Kato, M. Hatanaka, S. Harada	Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.	J Virol	68	233-9	1994	8254733	42	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8254733&dopt=Citation>8254733</a>	Este96	J. A. Este, K. De Vreese, M. Witvrouw, J. C. Schmit, A. M. Vandamme, J. Anne, J. Desmyter, G. W. Henson, G. Bridger, E. De Clercq	Antiviral activity of the bicyclam derivative JM3100 against drug- resistant strains of human immunodeficiency virus type 1.	Antiviral Res	29	297-307	1996	8739608	43	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8739608&dopt=Citation>8739608</a>	Este96a	J.A. Este, K. Van Laethem, A.M. Vandamme, J. Desmyter, E. De Clercq	Resistant phenotype of human immunodeficiency virus type 1 to dextran sulfate is conferred by specific amino acid substitutions in the gp120 molecule	Fifth International Workshop on HIV Drug Resistance Whistler, BC, Canada			1996		44		Este97	J.A. Este, D. Schols, K. De Vreese, D. Van Laethem, A.M. Vandamme, J. Desmyter, E. De Clercq	Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein	Molecular Pharmacology	52	98-104	19971997	9224818	45	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9224818&dopt=Citation>9224818</a>	Fitzgibbon92	J. E. Fitzgibbon, R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, D. T. Dubin	Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.	Antimicrob Agents Chemother	36	153-7	1992	1317143	46	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1317143&dopt=Citation>1317143</a>	Foli96	A. Foli, K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, R. Yarchoan	In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2- (phosphonomethoxy)ethyl]adenine (PMEA).	Antiviral Res	32	91-8	1996	8891168	47	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8891168&dopt=Citation>8891168</a>	Fujiwara98	T. Fujiwara, A. Sato, M. el-Farrash, S. Miki, K. Abe, Y. Isaka, M. Kodama, Y. Wu, L. B. Chen, H. Harada, H. Sugimoto, M. Hatanaka, Y. Hinuma	S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1	Antimicrob Agents Chemother	42	1340-5	1998	9624472	48	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9624472&dopt=Citation>9624472</a>	Gao92	Q. Gao, Z. X. Gu, M. A. Parniak, X. G. Li, M. A. Wainberg	In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.	J Virol	66	12-9	1992	1727474	49	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1727474&dopt=Citation>1727474</a>	Gao93	Q. Gao, Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, M. A. Wainberg	The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'- thiacytidine.	Antimicrob Agents Chemother	37	1390-2	1993	8392313	50	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8392313&dopt=Citation>8392313</a>	Garcia-Lerma03	Garcia-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W	A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation	J Virol	77(10)	5685-93	2003	12719561	51	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12719561&dopt=Citation>12719561</a>	Gashnikova03	Gashnikova N, Plyasunova O, Kiseleva Y, Fedyuk N, Pokrovsky A	In vitro study of resistance-associated genotypic mutations to nucleoside analogs	Nucleosides Nucleotides Nucleic Acids	22(5-8)	991-4	2003	14565328	52	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14565328&dopt=Citation>14565328</a>	Gatanaga02	Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H	Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors	J Biol Chem	277(8)	5952-61	2002	11741936	53	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11741936&dopt=Citation>11741936</a>	Geleziunas03	Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S	HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset)	Antivir Chem Chemother	14(1)	49-59	2003	12790516	54	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12790516&dopt=Citation>12790516</a>	Gong00	Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PF.	In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.	Antimicrobial Agents and Chemotherapy	44	2319-2326	2000	10952574	55	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10952574&dopt=Citation>10952574</a>	Gu92	Z. Gu, Q. Gao, X. Li, M. A. Parniak, M. A. Wainberg	Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'- dideoxyinosine and 2',3'-dideoxycytidine.	J Virol	66	7128-35	1992	1279198	56	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1279198&dopt=Citation>1279198</a>	Gu94	Z. Gu, Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, M. A. Wainberg	Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.	Antimicrob Agents Chemother	38	275-81	1994	7514855	57	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7514855&dopt=Citation>7514855</a>	Gulnik95	S. V. Gulnik, L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, J. W. Erickson	Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.	Biochemistry	34	9282-7	1995	7626598	58	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7626598&dopt=Citation>7626598</a>	Gurusinghe95	A. D. Gurusinghe, S. A. Land, C. Birch, C. McGavin, D. J. Hooker, G. Tachedjian, R. Doherty, N. J. Deacon	Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.	J Med Virol	46	238-43	1995	7561796	59	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7561796&dopt=Citation>7561796</a>	Hara97	Hara H, Fujihashi T, Sakata T, Kaji A, Kaji H	Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents	AIDS Res Hum Retroviruses	13	695-705	1997	9168238	60	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9168238&dopt=Citation>9168238</a>	Harrigan02	Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, Larder B, Kemp SD	A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance	J Virol	76(13)	6836-40	2002	12050397	61	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12050397&dopt=Citation>12050397</a>	Harrigan96	P. R. Harrigan, I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, B. A. Larder	Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.	J Virol	70	5930-4	1996	8709214	62	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8709214&dopt=Citation>8709214</a>	Hertogs00	Hertogs K, Bloor S, De Vroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Sturmer M, Alcorn T, Wegner S, van Houtte M, Miller V, Larder BA.	A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.	Antimicrobial Agents and Chemotherapy	44	568-573	2000	10681319	63	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10681319&dopt=Citation>10681319</a>	Ho94	D. D. Ho, T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, M. K. Singh	Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.	J Virol	68	2016-20	1994	8107264	64	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8107264&dopt=Citation>8107264</a>	Hodge96	Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, Grubb M, Jackson DA, Jadhav PK, Korant B, Lam PY, Maurin MB, Meek JL, Otto MJ, Rayner MM, Reid C, Sharpe TR, Shum L, Winslow DL, Erickson-Viitanen S	Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450	Chem Biol	3(4)	301-14	1996	8807858	65	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8807858&dopt=Citation>8807858</a>	Holz-Smith01	Holz-Smith SL, Sun IC, Jin L, Matthews TJ, Lee KH, Chen CH.	Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564.	Antimicrobial Agents and Chemotherapy	45	60-66	2001	11120945	66	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11120945&dopt=Citation>11120945</a>	Hooker96	D. J. Hooker, G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, N. J. Deacon	An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high- level resistance to 3'-azido-3'-deoxythymidine.	J Virol	70	8010-8	1996	8892925	67	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8892925&dopt=Citation>8892925</a>	Huang03	Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM	Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication	J Virol	77(2)	1512-23	2003	12502865	68	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12502865&dopt=Citation>12502865</a>	Imamichi00	Imamichi T, Sinha T, Imamichi H, Zhang YM, Metcalf JA, Falloon J, Lane HC	High level resistance to 3í-azido-3í-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1	J. Virol	74	1023-1028	2000	10623768	69	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10623768&dopt=Citation>10623768</a>	Jacobsen95	Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J	Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959	Virology	206(1)	527-34	1995	7831807	70	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7831807&dopt=Citation>7831807</a>	Kanbara01	Kanbara K, Sato S, Tanuma J, Tamamura H, Gotoh K, Yoshimori M, Kanamoto T, Kitano M, Fujii N, Nakashima H.	Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.	AIDS Res Hum Retroviruses	17(7)	615-22	2001	11375057	71	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11375057&dopt=Citation>11375057</a>	Kaplan94	A. H. Kaplan, S. F. Michael, R. S. Wehbie, M. F. Knigge, D. A. Paul, L. Everitt, D. J. Kempf, D. W. Norbeck, J. W. Erickson, R. Swanstrom	Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.	Proc Natl Acad Sci U S A	91	5597-601	1994	8202533	72	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8202533&dopt=Citation>8202533</a>	Kellam92	P. Kellam, C. A. Boucher, B. A. Larder	Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.	Proc Natl Acad Sci U S A	89	1934-8	1992	1371886	73	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1371886&dopt=Citation>1371886</a>	Kemp98	S. D. Kemp, C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, B. A. Larder	A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.	J Virol	72	5093-8	1998	9573280	74	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9573280&dopt=Citation>9573280</a>	Kempf01	Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA.	Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.	J Virol.	75(16)	7462-9	2001	11462018	75	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11462018&dopt=Citation>11462018</a>	Keulen96	W. Keulen, A. van Wijk, C. Boucher, B. Berkhout	Initial appearance of 184lle variant in 3TC-treated patients can be explained by the mutation bias of the HIV-1 RT enzyme	Fifth International Workshop on HIV Drug Resistance Whistler, BC, Canada			1996		76		Keulen97	Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B	Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase	J Virol	71(4)	3346-50	1997	9060708	77	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9060708&dopt=Citation>9060708</a>	King95	R.W. King, S. Garber, D.L. Winslow, C. Reid, L.T. Bacheler, E. Anton, M.J. Otto	Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors.	Antiviral Chemistry and Chemotherapy	669(9)	80-88	1995		78		King98	P.J. King, W. E. Robinson Jr.  	Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase.	Journal of Virology	72	8420-8424	1998	9733896	79	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9733896&dopt=Citation>9733896</a>	Kleim93	J. P. Kleim, R. Bender, U. M. Billhardt, C. Meichsner, G. Riess, M. Rosner, I. Winkler, A. Paessens	Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.	Antimicrob Agents Chemother	37	1659-64	1993	7692812	80	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7692812&dopt=Citation>7692812</a>	Kleim95	J. P. Kleim, R. Bender, R. Kirsch, C. Meichsner, A. Paessens, M. Rosner, H. Rubsamen-Waigmann, R. Kaiser, M. Wichers, K. E. Schneweis, et al	Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.	Antimicrob Agents Chemother	39	2253-7	1995	8619578	81	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8619578&dopt=Citation>8619578</a>	Kleim96	J. P. Kleim, M. Rosner, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, G. Riess	Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV- 1 replication results in the emergence of nucleoside RT-inhibitor- specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.	Proc Natl Acad Sci U S A	93	34-8	1996	8552634	82	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8552634&dopt=Citation>8552634</a>	Kleim97	J. P. Kleim, I. Winkler, M. Rosner, R. Kirsch, H. Rubsamen-Waigmann, A. Paessens, G. Riess	In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.	Virology	231	112-8	1997	9143309	83	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9143309&dopt=Citation>9143309</a>	Kleim99	J-P. Kleim, V. Burt, M. Maguire, R. Ferris, R.J. Hazen, G. Roberts, M. St. Clair.  	NNRTI GW420867X:  Comparative evaluation of the in vitro resistance profile.  	6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA. 		Abstract 600	1999		84		Koh03	Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H	Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro	Antimicrob Agents Chemother	47(10)	3123-9	2003	14506019	85	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14506019&dopt=Citation>14506019</a>	Kuhmann04	Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP	Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor	J Virol	78(6)	2790-807	2004	14990699	86	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14990699&dopt=Citation>14990699</a>	Labrosse00	Labrosse B, Treboute C, Alizon M.	Sensitivity to a nonpeptidic compound (RPR103611) blocking human    immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.	Journal of Virology	74(5)	2142-50	2000	10666243 	87	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10666243 &dopt=Citation>10666243 </a>	Labrosse97	B. Labrosse, O. Pleskoff, N. Sol, C. Jones, Y. Henin, M. Alizon	Antiviral and resistance studies of RPR103611, an inhibitor of HIV replication	Sixth International Workshop on HIV Drug Resistance, St. Petersburg, FL, USA			1997		88		Lacey94	S. F. Lacey, B. A. Larder	Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'- dideoxythymidine in cell culture.	Antimicrob Agents Chemother	38	1428-32	1994	7522429	89	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7522429&dopt=Citation>7522429</a>	Larder89	B. A. Larder, S. D. Kemp	Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).	Science	246	1155-8	1989	2479983	90	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2479983&dopt=Citation>2479983</a>	Larder91	B. A. Larder, K. E. Coates, S. D. Kemp	Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.	J Virol	65	5232-6	1991	1716689	91	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1716689&dopt=Citation>1716689</a>	Larder92	B. A. Larder	3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.	Antimicrob Agents Chemother	36	2664-9	1992	93128874	92	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=93128874&dopt=Citation>93128874</a>	Larder95	B. A. Larder, S. D. Kemp, P. R. Harrigan	Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.	Science	269	696-9	1995	7542804	93	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7542804&dopt=Citation>7542804</a>	Larder99	Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, Sturmer M, Staszewski S, Ren J, Stammers DK, StuartDI, Pauwels R.	A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1reverse transcriptase confer multinucleoside analog resistance.	Antimicrobial Agents and Chemotherapy	43	1961-1967	1999	10428920	94	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10428920&dopt=Citation>10428920</a>	Lawrence99	J. Lawrence, J. Schapiro, M. Winters, J. Montoya, A. Zolopa, R. Pesano, B. Efron, D. Winslow, T. C. Merigan	Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor- experienced persons	J Infect Dis	179	1356-64	1999	10228055	95	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10228055&dopt=Citation>10228055</a>	Li03	Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT	PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing	Proc Natl Acad Sci U S A	100(23)	13555-60	2003	14573704 	96	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=14573704 &dopt=Citation>14573704 </a>	Lin04	P F Lin, H T Ho, Y F Gong, I Dicker, N Zhou, L Fan, B McAuliffe, B Kimmel, B Nowicka-Sans, T Wang, J Kadow, G Yamanaka, Z Lin, N Meanwell, and R Colonno	Characterization of a Small Molecule HIV-1 Attachment Inhibitor BMS-488043: Virology, Resistance and Mechanism of Action	Abstract 534  11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA			2004		97		Lin96	P. F. Lin, H. Samanta, C. M. Bechtold, C. A. Deminie, A. K. Patick, M. Alam, K. Riccardi, R. E. Rose, R. J. White, R. J. Colonno	Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.	Antimicrob Agents Chemother	40	133-8	1996	8787894	98	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8787894&dopt=Citation>8787894</a>	Lin99	Lin PF, Gonzalez CJ, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg MA, Soriano V, Mellors JW, Colonno RJ	Stavudine resistance: an update on susceptibility following prolonged therapy	Antivir Ther	4(1)	21-8	1999	10682125	99	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10682125&dopt=Citation>10682125</a>	Lobato02	Lobato RL, Kim EY, Kagan RM, Merigan TC	Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase	AIDS Res Hum Retroviruse	18(10)	733-6	2002	12167282	100	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12167282&dopt=Citation>12167282</a>	Maass93	G. Maass, U. Immendoerfer, B. Koenig, U. Leser, B. Mueller, R. Goody, E. Pfaff	Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.	Antimicrob Agents Chemother	37	2612-7	1993	7509144	101	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7509144&dopt=Citation>7509144</a>	Maguire02	Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F, Parker H, May J, Snowden W	Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors	Antimicrob Agents Chemother	46(3)	731-8	2002	11850255	102	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11850255&dopt=Citation>11850255</a>	Marchand03	Marchand C, Johnson AA, Karki RG, Pais GC, Zhang X, Cowansage K, Patel TA, Nicklaus MC, Burke TR Jr, Pommier Y	Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S)	Mol Pharmacol	64(3)	600-9	2003	12920196	103	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12920196&dopt=Citation>12920196</a>	Masciari02	Masciari R, Cosco L, Diaco MC, Della DN, Ferraro T, Raimondi T, Ruperti B, Santandrea E	HIV-1: a case of RT67 deletion in a multi-treated non responder patient	New Microbiol	25(1)	83-8	2002	11837395	104	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11837395&dopt=Citation>11837395</a>	Mellors92	J. W. Mellors, G. E. Dutschman, G. J. Im, E. Tramontano, S. R. Winkler, Y. C. Cheng	In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase [published erratum appears in Mol Pharmacol 1992 Jul;42(1):174]	Mol Pharmacol	41	446-51	1992	1372083	105	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1372083&dopt=Citation>1372083</a>	Mellors93	J. W. Mellors, G. J. Im, E. Tramontano, S. R. Winkler, D. J. Medina, G. E. Dutschman, H. Z. Bazmi, G. Piras, C. J. Gonzalez, Y. C. Cheng	A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).	Mol Pharmacol	43192	11-6246-53	199319931993	7678690	106	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7678690&dopt=Citation>7678690</a>	Mellors95	J. W. Mellors, H. Z. Bazmi, R. F. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Weir, D. L. Mayers	Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. 	Antimicrob Agents Chemother	39	1087-92	1995	7542860	107	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7542860&dopt=Citation>7542860</a>	Mo03	Mo H, Lu L, Dekhtyar T, Stewart KD, Sun E, Kempf DJ, Molla A	Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir	Antiviral Res	59(3)	173-80	2003	12927307 	108	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12927307 &dopt=Citation>12927307 </a>	Mo96	H. Mo, M. Markowitz, P. Majer, S. K. Burt, S. V. Gulnik, L. I. Suvorov, J. W. Erickson, D. D. Ho	Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.	AIDS Res Hum Retroviruses	12	55-61	1996	8825619	109	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8825619&dopt=Citation>8825619</a>	Moeremans95a	M. Moeremans, M. De Raeymaeker, R. Van den Broeck, P. Stoffels, K. Andries	Genotypic analysis of HIV-1 isolates from patients receiving loviride alone or in combination with nucleoside reverse transcriptase inhibitor	Fourth International Workshop on HIV Drug Resistance Sardinia, Italy			1995		110		Molla96	A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, D. J. Kempf	Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.	Nat Med	2	760-6	1996	8673921	111	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8673921&dopt=Citation>8673921</a>	Montes02	Montes B, Segondy M.	Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.	J Med Virol.	66(3)	299-303	2002	11793380	112	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11793380&dopt=Citation>11793380</a>	Muzammil03	Muzammil S, Ross P, Freire E	A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance	Biochemistry	42(3)	631-8	2003	12534275	113	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12534275&dopt=Citation>12534275</a>	Nguyen94	M. H. Nguyen, R. F. Schinazi, C. Shi, N. M. Goudgaon, P. M. McKenna, J. W. Mellors	Resistance of human immunodeficiency virus type 1 to acyclic 6- phenylselenenyl- and 6-phenylthiopyrimidines.	Antimicrob Agents Chemother	38	2409-14	1994	7840579	114	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7840579&dopt=Citation>7840579</a>	Nunberg91	J. H. Nunberg, W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, M. E. Goldman	Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.	J Virol	65	4887-92	1991	1714522	115	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1714522&dopt=Citation>1714522</a>	Olmsted96	R. A. Olmsted, D. E. Slade, L. A. Kopta, S. M. Poppe, T. J. Poel, S. W. Newport, K. B. Rank, C. Biles, R. A. Morge, T. J. Dueweke, Y. Yagi, D. L. Romero, R. C. Thomas, S. K. Sharma, W. G. Tarpley	(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug- resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.	J Virol	70	3698-705	1996	8648704	116	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8648704&dopt=Citation>8648704</a>	Olsen99	Olsen DB, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC	Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors	J Biol Chem	274(34)	23699-701	1999	10446127	117	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10446127&dopt=Citation>10446127</a>	Otto93	M. J. Otto, S. Garber, D. L. Winslow, C. D. Reid, P. Aldrich, P. K. Jadhav, C. E. Patterson, C. N. Hodge, Y. S. Cheng	In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.	Proc Natl Acad Sci U S A	90	7543-7	1993	8356053	118	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8356053&dopt=Citation>8356053</a>	Paolucci03	Paolucci S, Baldanti F, Tinelli M, Maga G, Gerna G	Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy	AIDS	17(6)	924-7	2003	12660544	119	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12660544&dopt=Citation>12660544</a>	Parkin03	Parkin NT, Chappey C, Petropoulos CJ	Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance	AIDS	17(7)	955-61	2003	12700444 	120	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12700444 &dopt=Citation>12700444 </a>	Partaledis95	Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, Stuver CM, Byrn RA, Livingston DJ.	In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.	J Virol	69(9)	5228-5235	1995	7636964	121	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7636964&dopt=Citation>7636964</a>	Patick95	A. K. Patick, R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, P. F. Lin	Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.	J Virol	69	2148-52	1995	7884862	122	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7884862&dopt=Citation>7884862</a>	Patick96	A. K. Patick, H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, S. Webber	Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease [published erratum appears in Antimicrob Agents Chemother 1996 Jun;40(6):1575]	Antimicrob Agents Chemother	40	292-7	1996	8834868	123	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8834868&dopt=Citation>8834868</a>	Patick98	Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz M	Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir	Antimicrob Agents Chemother	42(10)	2637-44	1998	9756769	124	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9756769&dopt=Citation>9756769</a>	Pelemans97	H. Pelemans, R. Esnouf, A. Dunkler, M.A. Parniak, A-M. Vandamme, A. Karlsson, E. De Clercq, J-P. Kleim, J. Balzarini. 	Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.	J Virol	71(11)	8195-8203	1997	9343170	125	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9343170&dopt=Citation>9343170</a>	Prasad91	V. R. Prasad, I. Lowy, T. de los Santos, L. Chiang, S. P. Goff	Isolation and characterization of a dideoxyguanosine triphosphate- resistant mutant of human immunodeficiency virus reverse transcriptase.	Proc Natl Acad Sci U S A	88	11363-7	1991	1722328	126	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1722328&dopt=Citation>1722328</a>	Ranise03	Ranise A, Spallarossa A, Schenone S, Bruno O, Bondavalli F, Vargiu L, Marceddu T, Mura M, La Colla P, Pani A	Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives	J Med Chem	46(5)	768-81	2003	12593657 	127	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12593657 &dopt=Citation>12593657 </a>	Richard00	Richard N, Salomon H, Rando R, Mansour T, Bowlin TL, Wainberg MA.	Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and(-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.	Antimicrobial Agents and Chemotherapy	44	1127-1131	2000	10770740	128	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10770740&dopt=Citation>10770740</a>	Richard99	Richard N, Quan Y, Salomon H, Hsu M, Bedard J, Harrigan PR, Rando R, Mansour T, Bowlin TL, Wainberg MA	Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC)	Antivir Ther	4(3)	171-7	1999	12731757	129	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12731757&dopt=Citation>12731757</a>	Richman91	D. Richman, C. K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, J. Griffin	Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.	Proc Natl Acad Sci U S A	88	11241-5	1991	1722324	130	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1722324&dopt=Citation>1722324</a>	Richman93	D. D. Richman	Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.	 	37	1207-13	1993	8328771	131	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8328771&dopt=Citation>8328771</a>	Richman94	D. D. Richman, D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, et al	Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.	J Virol	68	1660-6	1994	7509000	132	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7509000&dopt=Citation>7509000</a>	Rimsky98	Rimsky LT, Shugars DC, Matthews TJ.	Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitor peptides.	J Virol	72(2)	986-993	1998	9444991	133	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9444991&dopt=Citation>9444991</a>	Rose94	B. Rose, J. Greytok, C. Bechtold, M. Alam, B. Terry, Gong Y.F. DeK. Vore, A. Patrick, R. Colono, Lin P	Combination therapy with two protease inhibitors as an approach to antiviral therapy	Third International Workshop on HIV Drug Resistance Kauai, HI, USA			1994		134		Rusconi00	Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'Arminio-Monforte A.	Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency                       virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.	Antimicrobial Agents and Chemotherapy	44	1328-1332	2000	10770770	135	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10770770&dopt=Citation>10770770</a>	Saag93	M. S. Saag, E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, et al	A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.	N Engl J Med	329	1065-72	1993	7690462	136	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7690462&dopt=Citation>7690462</a>	Schinazi93	R. F. Schinazi, R. M. Lloyd, M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, J. W. Mellors	Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.	Antimicrob Agents Chemother	37	875-81	1993	7684216	137	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7684216&dopt=Citation>7684216</a>	Schmit98	J. C. Schmit, K. Van Laethem, L. Ruiz, P. Hermans, S. Sprecher, A. Sonnerborg, M. Leal, T. Harrer, B. Clotet, V. Arendt, E. Lissen, M. Witvrouw, J. Desmyter, E. De Clercq, A. M. Vandamme	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries	AIDS	12	2007-15	1998	9814869	138	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9814869&dopt=Citation>9814869</a>	Schols98	Schols D, Este JA, Cabrera C, Cabrera C, De Clercq E.	T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell derived factor 1a contains mutations in envelope gp120 but does not show a switch in coreceptor use.	J Virol	72(5)	4032-4037	1998	9557691	139	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9557691&dopt=Citation>9557691</a>	Seki95	M. Seki, Y. Sadakata, S. Yuasa, M. Baba 	Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442	Antiviral Chemistry and Chemotherapy	6	73-9	1995		140		Shaw94	G. Shaw, X. Wei, Johnson V, M. Taylor, J. Decker, M. Kilby, J. Lifson, B. Hahn, Saag M	Nucleotide sequence analysis of HIV-1 RNA and DNA from plasma and PBMCs of patients treated with ZDV, ddI and nevirapine: rapid turnover and resistance development in vivo	Third International Workshop on HIV Drug Resistance Kauai, HI, USA			1994		141		Shirasaka95	T. Shirasaka, M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, et al	Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.	Proc Natl Acad Sci U S A	92	2398-402	1995	7534421	142	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7534421&dopt=Citation>7534421</a>	Smidt97	Smidt ML, Potts KE, Tucker SP, Blystone L, Stiebel TR Jr, Stallings WC, McDonald JJ, Pillay D, Richman DD, Bryant ML	A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A	Antimicrob Agents Chemother	41(3)	515-22	1997	9055985	144	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9055985&dopt=Citation>9055985</a>	Smith99	Smith RA, Klarmann GJ, Stray KM, von Schwedler UK, Schinazi RF, Preston BD, North TW.	A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.	Antimicrobial Agents and Chemotherapy	43	2077-2080	1999	10428942	145	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10428942&dopt=Citation>10428942</a>	Staszewski96	S.Staszewski, V. Miller, A. Kober, R. Colebunders, B. Vandercam, J. Delescluse, N. Clumeck, F. VanWanzeele, M. De Brabander, J De Cree, M. Moeremans, K. Andries, C. Boucher, P. Stoffels, P.A.J. Janssen	Evaluation of the efficacy and tolerance of RO18893, RO89439 (loviride) and placebo in asymptomatic HIV-1-infected patients	Antiviral Therapy	1(1)	42-50	1996	11322258	146	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11322258&dopt=Citation>11322258</a>	StClair91	M. H. St Clair, J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, B. A. Larder	Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.	Science	253	1557-9	1991	1716788	147	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1716788&dopt=Citation>1716788</a>	Tachedjian95	G. Tachedjian, D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, J. Mills	Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.	Virology	212	58-68	1995	7545854	148	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7545854&dopt=Citation>7545854</a>	Tanaka97	M. Tanaka, R. V. Srinivas, T. Ueno, M. F. Kavlick, F. K. Hui, A. Fridland, J. S. Driscoll, H. Mitsuya	In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.	Antimicrob Agents Chemother	41	1313-8	1997	9174190	149	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9174190&dopt=Citation>9174190</a>	Taylor00	Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF	Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]	Antivir Chem Chemother	11(4)	291-301	2000	10950391	150	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10950391&dopt=Citation>10950391</a>	Tisdale93	M. Tisdale, S. D. Kemp, N. R. Parry, B. A. Larder	Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.	Proc Natl Acad Sci U S A	90	5653-6	1993	7685907	151	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7685907&dopt=Citation>7685907</a>	Tisdale95	Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED	Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors	Antimicrob Agents Chemother	39(8)	1704-10	1995	7486905	152	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7486905&dopt=Citation>7486905</a>	Tisdale97	M. Tisdale, T. Alnadaf, D. Cousens	Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.	Antimicrob Agents Chemother	41	1094-8	1997	9145875	153	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9145875&dopt=Citation>9145875</a>	Trkola02	Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP	HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use	Proc Natl Acad Sci U S A	99(1)	395-400	2002	11782552 	154	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11782552 &dopt=Citation>11782552 </a>	Vandamme94	A. M. Vandamme, Z. Debyser, R. Pauwels, K. De Vreese, P. Goubau, M. Youle, B. Gazzard, P. A. Stoffels, G. F. Cauwenbergh, J. Anne, et al	Characterization of HIV-1 strains isolated from patients treated with TIBO R82913.	AIDS Res Hum Retroviruses	10	39-46	1994	7514016	155	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7514016&dopt=Citation>7514016</a>	Vandamme94a	A.-M. Vandamme 	Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection	Verhandelingen van de Koninklijke Academie voor Geneeskunde van Belgie	56	231-265	1994		156		VanLaethem00	Van Laethem K, Schmit JC, Pelemans H, Balzarini J, Witvrouw M, Perez-Perez MJ, Camarasa MJ, Esnouf RM, Aquaro S, Cenci A, Perno CF, Hermans P, Sprecher S, Ruiz L, Clotet B, Van Wijngaerden E, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM.	Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.	AIDS Research and Human Retroviruses	16	825-833	2000	10875608	157	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10875608&dopt=Citation>10875608</a>	VanRompay96	K. K. Van Rompay, J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, N. C. Pedersen	9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.	Antimicrob Agents Chemother	40	2586-91	1996	8913470	158	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8913470&dopt=Citation>8913470</a>	VanRompay97	Van Rompay KK, Greenier JL, Marthas ML, Otsyula MG, Tarara RP, Miller CJ, Pedersen NC	A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques	Antimicrob Agents Chemother	41	278-83	1997	9021180	159	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9021180&dopt=Citation>9021180</a>	VanRompay97a	K. Van Rompay, J. Cherrington, M. Marthas, E. Agatep, Z. Dehqanzada, P. Lamy, C. Berardi, N. Bischofberger, N. Pedersen	Therapeutic efficacy of PMPA treatment for infant macaques infected with PMPA-resistant simian immunodeficiency virus	Sixth International Workshop on HIV Drug Resistance St. Petersburg, FL, USA			1997		160		Vasudevachari92	Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG, Salzman NP	Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors	Virology	190(1)	269-77 	1992	1382341	161	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1382341&dopt=Citation>1382341</a>	Vasudevachari96	M. B. Vasudevachari, Y. M. Zhang, H. Imamichi, T. Imamichi, J. Falloon, N. P. Salzman	Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.	Antimicrob Agents Chemother	40	2535-41	1996	8913459	162	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8913459&dopt=Citation>8913459</a>	Vingerhoets04	J Vingerhoets, I De Baere, H Azijn, T Van den Bulcke, P McKenna, T Pattery, R Pauwels, and M-P de BÈthune	Antiviral Activity of TMC125 against a Panel of Site-directed Mutants Encompassing Mutations Observed in vitro and in vivo	Abstract 621  11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA			2004		163		Vrang93	L. Vrang, C. Rydergard, C. Ahgren, P. Engelhardt, M. Hogberg, N.G. Johansson, J. Kangasmetsa, P. Lind,  R. Noreen, C. Sahlberg, X. X. Zhou, A. Karlsson, C. Lopez, J.M. Morin, R.J. Ternansky, F.W. Bell, C.L. Jordan, M.D. Kinnick, J.A. Palkowitz, C.A. Parrish, P. Pranc, R.T. Vasileff, S.J. West, B.Oberg	Comparative rates of in vitro resistance development of HIV-1 tonon-nucleoside analog RT inhibitors	Antiviral Res	20 (S1)	77	1993		164		Wainberg99	Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM	In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA	Antivir Ther	4(2)	87-94	1999	10682153	165	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10682153&dopt=Citation>10682153</a>	Watkins03	Watkins T, Resch W, Irlbeck D, Swanstrom R	Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors	Antimicrob Agents Chemother	47(2)	759-69	2003	12543689 	166	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12543689 &dopt=Citation>12543689 </a>	Wei02	Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC	Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy	Antimicrob Agents Chemother	46(6)	1896-905	2002	12019106	167	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12019106&dopt=Citation>12019106</a>	Weinheimer04	S. Weinheimer, L. Dicotto, J. Friborg, R. Colonno	Recombinant HIV Gag-Pol Proteins Display the Unique I150L Phenotype of Selective Atazanavir Resistance and Increased Susceptibility to Other PIs	Abstract 625 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA			2004		168		Winslow96	D. L. Winslow, S. Garber, C. Reid, H. Scarnati, D. Baker, M. M. Rayner, E. D. Anton	Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.	AIDS	10	1205-9 	1996	8883581	169	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8883581&dopt=Citation>8883581</a>	Winters98	M. A. Winters, K. L. Coolley, Y. A. Girard, D. J. Levee, H. Hamdan, R. W. Shafer, D. A. Katzenstein, T. C. Merigan	A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors	J Clin Invest	102	1769-75	1998	9819361	170	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9819361&dopt=Citation>9819361</a>	Winters98a	Winters MA, Schapiro JM, Lawrence J, Merigan TC	Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment	J Virol	72(6)	5303-6	1998	9573309	171	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9573309&dopt=Citation>9573309</a>	Witvrouw98	Witvrouw M, Arranz ME, Pannecouque C, Declercq R, Jonckheere H, Schmit J-C, Vandamme A-M, Diaz JA, Ingate ST, Desmyter J, Esnouf R, Van Meervelt L, Vega S, Balzarini J, De Clercq E.	1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TDD) derivatives:  a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.	Antimicrob Agents Chemother	42(3)	618-623	1998	9517942	172	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9517942&dopt=Citation>9517942</a>	Yoshimura99	K. Yoshimura, R. Kato, K. Yusa, M. F. Kavlick, V. Maroun, A. Nguyen, T. Mimoto, T. Ueno, M. Shintani, J. Falloon, H. Masur, H. Hayashi, J. Erickson, Mitsuya, H. 	JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1	Proc Natl Acad Sci U S A	96	8675-80	1999	10411934	173	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10411934&dopt=Citation>10411934</a>	Yoshimura99a	Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H.	In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.	Antimicrobial Agents and Chemotherapy	43	2479-2483	1999	10508028	174	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10508028&dopt=Citation>10508028</a>	Young95	S. D. Young, S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, et al	L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.	Antimicrob Agents Chemother	39	2602-5	1995	8592986	175	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8592986&dopt=Citation>8592986</a>	Zhang94	D. Zhang, A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, R. T. D'Aquila	Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.	Antimicrob Agents Chemother	38	282-7	1994	7514856	176	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7514856&dopt=Citation>7514856</a>	Zhang95	H. Zhang, L. Vrang, K. Backbro, P. Lind, C. Sahlberg, T. Unge, B. Oberg	Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.	Antiviral Res	28	331-42	1995	8669892	177	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8669892&dopt=Citation>8669892</a>	Ziermann00	Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT.	A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.	Journal of Virology	74	4414-4419	2000	10756056	178	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10756056&dopt=Citation>10756056</a>	Brandin03	Eleonor Brandin, Lena Lindborg, Katarina Gyllensten, Christina Broström, Lars Hagberg,Magnus Gisslen, Björn Tuvesson,Anders Blaxhult, Jan Albert	pol Gene Sequence Variation in Swedish HIV-2 Patients Failing Antiretroviral Therapy	AIDS Research And Human Retroviruses	19(7)	543-550	2003	12908931	179	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12908931&dopt=Citation>12908931</a>	Gosselin94	Gosselin G, Schinazi RF, Sommadossi JP, Mathe C, Bergogne MC, Aubertin AM, Kirn A, Imbach JL.	Anti-Human Immunodeficiency Virus Activities of the beta-L Enantiomer of 2’,3’-Dideoxycytidine and Its 5-Fluoro Derivative In Vitro	Antimicrobial Agents and Chemotherapy	38(6)	292-1297	1994	8092827	180	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8092827&dopt=Citation>8092827</a>	Lin03	Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R	A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding	Proc Natl Acad Sci U S A	100(19)	11013-11018	2003	12930892	181	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=12930892&dopt=Citation>12930892</a>	Baxter06	Baxter J, Schapiro J, Boucher C, Kohlbrenner V, Hall D, Scherer J, Mayers D	Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir	Journal of Virology	80(21)	10794-10801	2006	16928764	211	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16928764&dopt=Citation>16928764</a>	21Nikolenko07	Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, Coffin JM, Pathak VK.	Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance	PNAS	104(1)	317-322	2007	17179211	213	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17179211&dopt=Citation>17179211</a>	1Svicher06	Svicher V, Sing T, Santoro MM, Forbici F, Rodriguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF.	Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors	Journal of Virology	80(14)	7186-7198	2006	16809324	214	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16809324&dopt=Citation>16809324</a>	14Cole06	A.L. Cole, O.O. Yang, A.D. Warren, A.J. Waring, R.I. Lehrer, A.M. Cole	HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41	J Immunol	176(11)	6900-5	2006	16709850	217	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16709850&dopt=Citation>16709850</a>	11Kehlenbeck06	S. Kehlenbeck, U. Betz, A. Birkmann, B. Fast, A.H. Goller, K. Henninger, T. Lowinger, D. Marrero, A. Paessens, D. Paulsen, V. Pevzner, R. Schohe-Loop, H. Tsujishita, R. Welker, J. Kreuter, H. Rubsamen-Waigmann, F. Dittmer	Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore	J Virol	80(14)	6883-94	2006	16809294	218	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16809294&dopt=Citation>16809294</a>	14Waheed06	A.A. Waheed, S.D. Ablan, M.K. Mankowski, J.E. Cummins, R.G. Ptak, C.P. Schaffner, E.O. Freed	Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants	J Biol Chem	281(39)	28699-711	2006	16882663	219	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16882663&dopt=Citation>16882663</a>	39Sevigny06	G. Sevigny, B. Stranix, B. Tian, A. Dubois, G. Sauve, C. Petropoulos, Y. Lie, N. Hellmann, B. Conway, J. Yelle	Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor	Antiviral Res	70(2)	17-20	2006	16473417	220	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16473417&dopt=Citation>16473417</a>	2Nijhuis07	M. Nijhuis, N.M. van Maarseveen, S. Lastere, P. Schipper, E. Coakley, B. Glass, M. Rovenska, D. de Jong, C. Chappey, I.W. Goedegebuure, G. Heilek-Snyder, D. Dulude, N. Cammack, L. Brakier-Gingras, J. Konvalinka, N. Parkin, H.G. Krausslich, F. Brun-Vezinet, C.A. Boucher	A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism	PLoS Med	4(1)	e36	2007	17227139	221	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17227139&dopt=Citation>17227139</a>	1Kovalevsky06	A.Y. Kovalevsky, Y. Tie, F. Liu, P.I. Boross, Y.F. Wang, S. Leshchenko, A.K. Ghosh, R.W. Harrison, I.T. Weber	Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M	J Med Chem	49(4)	1379-87	2006	16480273	222	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16480273&dopt=Citation>16480273</a>	4Zhang06	Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z	Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase	Antimicrobial Agents Chemotherapy	50(8)	2772-2781	2006	16870771	233	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16870771&dopt=Citation>16870771</a>	8Zhang06b	Zhang Z, Xu W, Koh YH, Shim JH, Girardet JL, Yeh LT, Hamatake, RK, Hong Z	A Novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors	Antimicrobial Agents Chemotherapy	51(2)	429-437	2007	17116677	234	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17116677&dopt=Citation>17116677</a>	2Adamson06	C.S. Adamson, S.D. Ablan, I. Boeras, R. Goila-Gaur, F. Soheilian, K. Nagashima, F. Li, K. Salzwedel, M. Sakalian, C.T. Wild, E.O. Freed	In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)	J Virol	80(22)	10957-71	2006	16956950	236	<a href=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16956950&dopt=Citation>16956950</a>	22